1
|
Tinajero-Díaz E, Salado-Leza D, Gonzalez C, Martínez Velázquez M, López Z, Bravo-Madrigal J, Knauth P, Flores-Hernández FY, Herrera-Rodríguez SE, Navarro RE, Cabrera-Wrooman A, Krötzsch E, Carvajal ZYG, Hernández-Gutiérrez R. Green Metallic Nanoparticles for Cancer Therapy: Evaluation Models and Cancer Applications. Pharmaceutics 2021; 13:1719. [PMID: 34684012 PMCID: PMC8537602 DOI: 10.3390/pharmaceutics13101719] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2021] [Revised: 09/29/2021] [Accepted: 10/05/2021] [Indexed: 12/15/2022] Open
Abstract
Metal-based nanoparticles are widely used to deliver bioactive molecules and drugs to improve cancer therapy. Several research works have highlighted the synthesis of gold and silver nanoparticles by green chemistry, using biological entities to minimize the use of solvents and control their physicochemical and biological properties. Recent advances in evaluating the anticancer effect of green biogenic Au and Ag nanoparticles are mainly focused on the use of conventional 2D cell culture and in vivo murine models that allow determination of the half-maximal inhibitory concentration, a critical parameter to move forward clinical trials. However, the interaction between nanoparticles and the tumor microenvironment is not yet fully understood. Therefore, it is necessary to develop more human-like evaluation models or to improve the existing ones for a better understanding of the molecular bases of cancer. This review provides recent advances in biosynthesized Au and Ag nanoparticles for seven of the most common and relevant cancers and their biological assessment. In addition, it provides a general idea of the in silico, in vitro, ex vivo, and in vivo models used for the anticancer evaluation of green biogenic metal-based nanoparticles.
Collapse
Affiliation(s)
- Ernesto Tinajero-Díaz
- Departament d’Enginyeria Química, Universitat Politècnica de Catalunya, ETSEIB, Diagonal 647, 08028 Barcelona, Spain;
- Biotecnología Médica y Farmacéutica, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, A.C., Av. Normalistas 800, Col. Colinas de La Normal, Guadalajara 44270, Mexico; (M.M.V.); (J.B.-M.); (F.Y.F.-H.); (S.E.H.-R.)
| | - Daniela Salado-Leza
- Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava, Zona Universitaria, San Luis Potosí 78210, Mexico; (D.S.-L.); (C.G.)
- Cátedras CONACyT, México City 03940, Mexico
| | - Carmen Gonzalez
- Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava, Zona Universitaria, San Luis Potosí 78210, Mexico; (D.S.-L.); (C.G.)
| | - Moisés Martínez Velázquez
- Biotecnología Médica y Farmacéutica, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, A.C., Av. Normalistas 800, Col. Colinas de La Normal, Guadalajara 44270, Mexico; (M.M.V.); (J.B.-M.); (F.Y.F.-H.); (S.E.H.-R.)
| | - Zaira López
- Centro Universitario de la Ciénega, Cell Biology Laboratory, Universidad de Guadalajara, Av. Universidad 1115, Ocotlán 47810, Mexico; (Z.L.); (P.K.)
| | - Jorge Bravo-Madrigal
- Biotecnología Médica y Farmacéutica, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, A.C., Av. Normalistas 800, Col. Colinas de La Normal, Guadalajara 44270, Mexico; (M.M.V.); (J.B.-M.); (F.Y.F.-H.); (S.E.H.-R.)
| | - Peter Knauth
- Centro Universitario de la Ciénega, Cell Biology Laboratory, Universidad de Guadalajara, Av. Universidad 1115, Ocotlán 47810, Mexico; (Z.L.); (P.K.)
| | - Flor Y. Flores-Hernández
- Biotecnología Médica y Farmacéutica, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, A.C., Av. Normalistas 800, Col. Colinas de La Normal, Guadalajara 44270, Mexico; (M.M.V.); (J.B.-M.); (F.Y.F.-H.); (S.E.H.-R.)
| | - Sara Elisa Herrera-Rodríguez
- Biotecnología Médica y Farmacéutica, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, A.C., Av. Normalistas 800, Col. Colinas de La Normal, Guadalajara 44270, Mexico; (M.M.V.); (J.B.-M.); (F.Y.F.-H.); (S.E.H.-R.)
| | - Rosa E. Navarro
- Departamento de Biología Celular y Desarrollo, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Circuito Exterior s/n, Ciudad Universitaria, México City 04510, Mexico;
| | - Alejandro Cabrera-Wrooman
- Centro Nacional de Investigación y Atención de Quemados, Laboratory of Connective Tissue, Instituto Nacional de Rehabilitación “Luis Guillermo Ibarra Ibarra”, México City 14389, Mexico; (A.C.-W.); (E.K.)
| | - Edgar Krötzsch
- Centro Nacional de Investigación y Atención de Quemados, Laboratory of Connective Tissue, Instituto Nacional de Rehabilitación “Luis Guillermo Ibarra Ibarra”, México City 14389, Mexico; (A.C.-W.); (E.K.)
| | - Zaira Y. García Carvajal
- Biotecnología Médica y Farmacéutica, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, A.C., Av. Normalistas 800, Col. Colinas de La Normal, Guadalajara 44270, Mexico; (M.M.V.); (J.B.-M.); (F.Y.F.-H.); (S.E.H.-R.)
| | - Rodolfo Hernández-Gutiérrez
- Biotecnología Médica y Farmacéutica, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, A.C., Av. Normalistas 800, Col. Colinas de La Normal, Guadalajara 44270, Mexico; (M.M.V.); (J.B.-M.); (F.Y.F.-H.); (S.E.H.-R.)
| |
Collapse
|
2
|
Dai X, Liang Z, Liu L, Guo K, Xu S, Wang H. Silencing of MALAT1 inhibits migration and invasion by sponging miR‑1‑3p in prostate cancer cells. Mol Med Rep 2019; 20:3499-3508. [PMID: 31485645 PMCID: PMC6755148 DOI: 10.3892/mmr.2019.10602] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2018] [Accepted: 02/19/2019] [Indexed: 12/28/2022] Open
Abstract
Prostate cancer is a common malignancy with a high mortality rate. Long non-coding RNA metastasis associated with lung adenocarcinoma transcript 1 (MALAT1) has been reported to serve tumor-promoting roles. However, the underlying mechanism requires further examination. In the present study, it was demonstrated that MALAT1 was increased while microRNA (miR/miRNA)-1-3p was decreased in prostate cancer cell lines. The silencing of MALAT1 inhibited migration, invasion and epithelial-mesenchymal transition, when epithelial (E)-cadherin expression level was increased, and neural (N)-cadherin, vimentin, Slug and Snail expression levels were decreased. Dual-luciferase reporter assay results demonstrated that miR-1-3p bound to MALAT1 and coronin 1C (CORO1C) 3′ untranslated region, and MALAT1 competed with CORO1C for the binding sites of miR-1-3p. MALAT1 inhibited the expression of miR-1-3p and vice versa. MALAT1 knockdown induced the decline of CORO1C, which was subsequently recovered by the miR-1-3p inhibitor. In addition, by inhibiting miR-1-3p or overexpressing CORO1C, the silencing of MALAT1-induced phenotypic alterations were restored. In conclusion, MALAT1 serving as a degradable miRNA sponge, may sequester miR-1-3p from CORO1C and by silencing MALAT1, migration, invasion and epithelial-mesenchymal transition may be inhibited in prostate cancer cells. MALAT1 and CORO1C may serve as novel clinical therapeutic targets for prostate cancer.
Collapse
Affiliation(s)
- Xiaofan Dai
- Department of Andrology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
| | - Zuowen Liang
- Human Sperm Bank of Jilin Province, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
| | - Lingyun Liu
- Department of Andrology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
| | - Kaimin Guo
- Department of Andrology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
| | - Shengqi Xu
- Department of Andrology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
| | - Hongliang Wang
- Department of Andrology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
| |
Collapse
|
3
|
Chen H, Shen HX, Lin YW, Mao YQ, Liu B, Xie LP. Small RNA-induced INTS6 gene up-regulation suppresses castration-resistant prostate cancer cells by regulating β-catenin signaling. Cell Cycle 2018; 17:1602-1613. [PMID: 29895194 DOI: 10.1080/15384101.2018.1475825] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022] Open
Abstract
Small RNAs play an important role in gene regulatory networks. The gene suppressive effect of small RNAs was previously the dominant focus of studies, but during the recent decade, small RNA-induced gene activation has been reported and has become a notable gene manipulation technique. In this study, a putative tumor suppressor, INTS6, was activated by introducing a promoter-targeted small RNA (dsRNA-915) into castration-resistant prostate cancer (CRPC) cells. Unique dynamics associated with the gene upregulation phenomenon was observed. Following gene activation, cell proliferation and motility were suppressed in vitro. Downregulation of Wnt/β-catenin signaling was observed during the activation period, and the impairment of β-catenin degradation reversed the tumor suppressor effects of INTS6. These results suggest the potential application of small activating RNAs in targeted gene therapy for CRPC.
Collapse
Affiliation(s)
- Hong Chen
- a Department of Urology , The First Affiliated Hospital, School of Medicine, Zhejiang University , Hangzhou , Zhejiang Province , China
| | - Hai-Xiang Shen
- a Department of Urology , The First Affiliated Hospital, School of Medicine, Zhejiang University , Hangzhou , Zhejiang Province , China
| | - Yi-Wei Lin
- a Department of Urology , The First Affiliated Hospital, School of Medicine, Zhejiang University , Hangzhou , Zhejiang Province , China
| | - Ye-Qing Mao
- a Department of Urology , The First Affiliated Hospital, School of Medicine, Zhejiang University , Hangzhou , Zhejiang Province , China
| | - Ben Liu
- a Department of Urology , The First Affiliated Hospital, School of Medicine, Zhejiang University , Hangzhou , Zhejiang Province , China
| | - Li-Ping Xie
- a Department of Urology , The First Affiliated Hospital, School of Medicine, Zhejiang University , Hangzhou , Zhejiang Province , China
| |
Collapse
|
4
|
Prostate Cancer Stem Cells: Research Advances. Int J Mol Sci 2015; 16:27433-49. [PMID: 26593898 PMCID: PMC4661894 DOI: 10.3390/ijms161126036] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2015] [Revised: 09/26/2015] [Accepted: 10/08/2015] [Indexed: 12/18/2022] Open
Abstract
Cancer stem cells have been defined as cells within a tumor that possesses the capacity to self-renew and to cause the heterogeneous lineages of cancer cells that comprise the tumor. Experimental evidence showed that these highly tumorigenic cells might be responsible for initiation and progression of cancer into invasive and metastatic disease. Eradicating prostate cancer stem cells, the root of the problem, has been considered as a promising target in prostate cancer treatment to improve the prognosis for patients with advanced stages of the disease.
Collapse
|
5
|
Derosa L, Galli L, Orlandi P, Fioravanti A, Di Desidero T, Fontana A, Antonuzzo A, Biasco E, Farnesi A, Marconcini R, Francia G, Danesi R, Falcone A, Bocci G. Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients. Cancer 2014; 120:3923-31. [DOI: 10.1002/cncr.28953] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2014] [Revised: 07/07/2014] [Accepted: 07/14/2014] [Indexed: 11/09/2022]
Affiliation(s)
- Lisa Derosa
- Oncology Unit 2; University Hospital of Pisa; Pisa Italy
| | - Luca Galli
- Oncology Unit 2; University Hospital of Pisa; Pisa Italy
| | - Paola Orlandi
- Division of Pharmacology; Department of Experimental and Clinical Medicine; University of Pisa; Pisa Italy
| | - Anna Fioravanti
- Division of Pharmacology; Department of Experimental and Clinical Medicine; University of Pisa; Pisa Italy
| | - Teresa Di Desidero
- Division of Pharmacology; Department of Experimental and Clinical Medicine; University of Pisa; Pisa Italy
| | - Andrea Fontana
- Oncology Unit 2; University Hospital of Pisa; Pisa Italy
| | | | - Elisa Biasco
- Oncology Unit 2; University Hospital of Pisa; Pisa Italy
| | | | | | - Giulio Francia
- Border Biomedical Research Center; University of Texas at El Paso; El Paso Texas
| | - Romano Danesi
- Division of Pharmacology; Department of Experimental and Clinical Medicine; University of Pisa; Pisa Italy
| | - Alfredo Falcone
- Oncology Unit 2; University Hospital of Pisa; Pisa Italy
- Tumor Institute of Tuscany; Florence Italy
| | - Guido Bocci
- Division of Pharmacology; Department of Experimental and Clinical Medicine; University of Pisa; Pisa Italy
- Tumor Institute of Tuscany; Florence Italy
| |
Collapse
|
6
|
Trendel JA. The hurdle of antiandrogen drug resistance: drug design strategies. Expert Opin Drug Discov 2013; 8:1491-501. [PMID: 24206221 DOI: 10.1517/17460441.2013.855194] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION Prostate cancer is the second most common cancer death in men after lung cancer, due to distant metastases. While distant prostate cancer is typically castrate resistant, it is not necessarily androgen independent. For this reason, a review of the literature regarding the pathways involved in androgen signaling and therapeutic regimens to treat distant metastases is beneficial to increasing the survival rate of prostate cancer patients. AREAS COVERED In this article, the author reviews the literature from the past decade covering metastatic hormone refractory prostate cancer with the aim to examine and identify pathways, therapeutic targets and current therapies for treating castrate-resistant disease. As this area is lacking, the author aims to provide the reader with knowledge of the molecular consequences of castrate resistant prostate cancer, the current treatment paradigms and future directions. EXPERT OPINION While there have been advances in the treatment of castrate resistant prostate cancer, only minimal advances have been made in overall survival rate. Due to aberrant mutations and activation in the androgen receptor gene, and the complexity of cell signaling within prostate cancer, the androgen receptor should remain a main target for drug discovery efforts. This author believes that designing compounds that will reduce the activation of the androgen receptor may hold the key to a cure in the future.
Collapse
Affiliation(s)
- Jill A Trendel
- University of Toledo, Center for Drug Design and Development , 3000 Arlington Ave MS 1015 Toledo, OH 43614 , USA +1 419 383 1536 ;
| |
Collapse
|
7
|
Ren S, Liu Y, Xu W, Sun Y, Lu J, Wang F, Wei M, Shen J, Hou J, Gao X, Xu C, Huang J, Zhao Y, Sun Y. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. J Urol 2013; 190:2278-87. [PMID: 23845456 DOI: 10.1016/j.juro.2013.07.001] [Citation(s) in RCA: 235] [Impact Index Per Article: 21.4] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/01/2013] [Indexed: 02/07/2023]
Abstract
PURPOSE To understand the role of MALAT-1 in prostate cancer we evaluated its expression in prostate cancer tissues and cell lines. We also studied the therapeutic effects of MALAT-1 silencing on castration resistant prostate cancer cells in vitro and in vivo. MATERIALS AND METHODS Quantitative reverse transcriptase-polymerase chain reaction was used to detect MALAT-1 expression in prostate cancer tissues and cell lines. siRNA against MALAT-1 was designed and the silencing effect was examined by quantitative reverse transcriptase-polymerase chain reaction. The biological effects of MALAT-1 siRNA on cells were investigated by examining cell proliferation using a cell counting kit and cell colony assays as well as cell migration by in vitro scratch assay, cell invasion by Transwell® invasion assay and cell cycle by flow cytometry. We further investigated the effect of therapeutic siRNA targeting MALAT-1 on castration resistant prostate cancer in vivo. RESULTS MALAT-1 was up-regulated in human prostate cancer tissues and cell lines. Higher MALAT-1 expression correlated with high Gleason score, prostate specific antigen, tumor stage and castration resistant prostate cancer. MALAT-1 down-regulation by siRNA inhibited prostate cancer cell growth, invasion and migration, and induced castration resistant prostate cancer cell cycle arrest in the G0/G1 phases. Importantly, intratumor delivery of therapeutic siRNA targeting MALAT-1 elicited delayed tumor growth and reduced metastasis of prostate cancer xenografts in castrated male nude mice, followed by the concomitant prolongation of survival of tumor bearing mice. CONCLUSIONS MALAT-1 may be needed to maintain prostate tumorigenicity and it is involved in prostate cancer progression. Thus, MALAT-1 may serve as a potential therapeutic target for castration resistant prostate cancer.
Collapse
Affiliation(s)
- Shancheng Ren
- Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Current World Literature. Curr Opin Urol 2013. [DOI: 10.1097/mou.0b013e3283605159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|